---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-003178"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:43:46.151279+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Phio Pharmaceuticals Q1 2024 net loss narrows to $2.2M; cash at $6.5M

## Summary
- Cash of $6.5M at March 31, 2024, down from $8.5M at Dec 31, 2023.
- Net loss of $2.2M for Q1 2024 vs $3.6M in prior-year quarter; R&D expenses fell 46% to $1.1M.
- Phase 1b trial of PH-762 in skin cancers has enrolled 3 patients at 4 U.S. sites.
- USPTO granted patents for INTASYL compounds RXI-185 and RXI-231 targeting age-related skin disorders.

## SEC filing metadata
- accession: 0001683168-24-003178
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316824003178/0001683168-24-003178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316824003178/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-003178
- JSON: https://secwatch.observer/filing/0001683168-24-003178.json
- Plain text: https://secwatch.observer/filing/0001683168-24-003178.txt

## Key facts
- Earnings Releases
  Phio Pharmaceuticals Corp. reported the three months ended March 31, 2024 results: net income Net loss was $2.2 million for the three months ended March 31, 2024.
  - Period: the three months ended March 31, 2024
  - Net income: Net loss was $2.2 million for the three months ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the period ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316824003178/0001683168-24-003178-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.